You are here

USE OF ALBUTEROL IN SPINAL CORD INJURY

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43NS041823-01A1
Agency Tracking Number: NS041823
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
MOTOGEN, INC. 3 PINE VIEW RD
MOUNT KISCO, NY 10549
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 RICHARD ZEMAN
 (914) 594-4029
 ZEMAN@NYMC.EDU
Business Contact
 JOS ETLINGER
Phone: (914) 594-4028
Email: JOSEPH_ETLINGER@NYMC.EDU
Research Institution
N/A
Abstract

The overall goal of this project is to demonstrate the ability of the f32-adrenoceptor agonist, albuterol, an FDA approved therapeutic for obstructive respiratory conditions and xirradiation in combination to oppose irreversible loss of locomotor function due to contusion, the most common type of spinal cord injury (SCI). At present, only methyiprednisolone has been shown to have efficacy in humans for SCI. However, the extent of recovery is limited so that additional or alternative treatments are needed. Potentially superior countermeasures are available, but require a demonstration of efficacy in an appropriate animal model of spinal cord contusion injury prior to use in patients. The proposed studies are an outgrowth of previous work in which J32-agonists or x-irradiation enhanced recovery of locomotor function following SCI in rats. Recovery of locomotor function, in turn, correlated with sparing of myelinated white matter at the injury site by these agents. We will determine (1) the therapeutic window and optimum dose of albuterol for sparing spinal cord tissue and locomotor function following contusion in an established model of SCI developed by the Multicenter Animal Spinal Cord Injury Study (MASCIS) (2) and the efficacy of albuterol and x-irradiation in combination. Optimization of beta2-agonist treatment and x-irradiation of the contused spinal cord may lead to a useful therapeutic modality for SCI.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government